To determine the efficacy of forskolin in preventing asthma attacks, we performed a single-blinded clinical study in children and adult out-patients at a public hospital in Mexico. Forty patients of either sex with mild persistent or moderate persistent asthma were assigned randomly to 6 months of treatment with forskolin at 10 mg/day orally (capsules) or with two inhalations of sodium cromoglycate every 8 h, i.e. three times a day. The number of patients who had asthma attacks during the treatment period was significantly lower among those receiving forskolin (8/20, 40%) than among those receiving sodium cromoglycate (17/20, 85%). Values of forced expiratory volume in 1 s and forced expiratory flow, mid-phase, were similar in the two groups during the treatment period. We conclude that forskolin is more effective than sodium cromoglycate in preventing asthma attacks in patients with mild persistent or moderate persistent asthma.
Introduction
The prevalence of asthma has increased markedly in recent years. In the USA this disease affects about 15 million people, of whom 5 million are children. 1 One of the factors believed to contribute to the increase in the prevalence of asthma is exposure to environmental polluting agents, a source of the free radicals that are known to cause relevant damage. 2 -5 Previous studies have demonstrated the relevance of free radicals in the physiopathology of asthma, the indication being that in patients with asthma an antioxidant-deficient diet is associated with an increase in the frequency of asthma attacks. 2, 5, 6 On the other hand, because of the inflammatory component of this disease, regular and prophylactic antiinflammatory treatment is important in the long-term control of symptoms.
Most of the medicines used in the prophylaxis of asthma attacks do not have antioxidant effects. One of the drugs with an antioxidant effect that has been used in the treatment of salbutamol tachyphylaxis is forskolin. 7, 8 Forskolin is a compound isolated from the root, flowers and other parts of Coleus forskohlii, a plant native to India. 9 Many of the effects induced by forskolin result from the activation of adenylate cyclase, which increases the intracellular level of cAMP. 10, 11 In asthma, the action of forskolin may increase the level of cAMP in the bronchial smooth muscle, reducing bronchial reactivity with a consequent bronchodilator effect. 12 In addition, it has been shown that forskolin has inhibitory actions on the production of interleukins (IL-13, IL-5 and IL-1β), eotaxin and histamine. 7,8,13 -22 The antioxidant and bronchial anti-inflammatory actions of forskolin are explained by an inhibitory action on macrophages, with subsequent decreases in the levels of thromboxane B 2 and superoxide radicals. Because of these characteristics, forskolin has potential for use in the treatment of diseases such as cardiopathies, hypertension, diabetes and asthma. 23, 24 In addition, forskolin may be useful as a prophylactic treatment in the prevention of asthma attacks. So far, however, none of the wide range of therapeutic medications used in the long-term control of asthma has been demonstrated to have an antioxidant action. We therefore decided to examine the effectiveness of forskolin as a long-term treatment for the prevention of asthma attacks. In this study, our main objective was to compare the effectiveness of forskolin with that of sodium cromoglycate in the prevention of asthmatic attacks in children and adults who presented with slight persistent or moderate persistent asthma.
Patients and methods PATIENTS
A single-blinded clinical trial was carried out in patients who presented for outpatient consultation at the Family Medicine Hospital of the Instituto Mexicano del Seguro Social, Manzanillo, Colima, Mexico. The patients were classified with respect to asthma according to the 'Highlights of the Expert Panel Report 2' from the 'Guidelines for the Diagnosis and Management of Asthma'. 25 Patients of either sex were selected who presented with mild or moderate asthma. Patients who were dehydrated, who had taken β-agonists or steroids 12 h before presentation or who had a probable respiratory tract infection were not enrolled in the study. Patients with a respiratory complication or without a respiratory improvement with the forskolin treatment, intolerance or allergy to the drugs administered in this study, patients with rhinitis or sinusitis, patients who smoked and patients who chose to leave the study were not included in the analysis. An informed consent form was signed by each patient or by the child's parents before the beginning of the study, which was approved by the Ethics Committee of our hospital. During the study, the patients did not use any medication other than the study drugs. Because of the lack of studies on the efficacy of forskolin as a prophylactic treatment for asthma attacks, it was not possible to determine a sample size. We therefore assessed at each clinic visit the degree to which the patients had complied with their instructions for treatment.
INTERVENTIONS
Patients were assigned randomly to one of two treatments. Patients in the experimental group were treated with forskolin (Prolongevity Forskolin, 10 mg capsules; Life Extension Foundation Buyers Club, Fort Lauderdale, Florida, USA) at 10 mg/day orally for 6 months. Patients in the control group were treated with sodium cromoglycate (Intal 5; Aventis Laboratories, Mexico; 5 mg per inhalation, two inhalations every 8 h; i.e. three times per day) for 6 months.
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Forskolin for prevention of asthma attacks OUTCOME To determine the baseline values of forced expiratory volume in 1 s (FEV 1 ) and forced expiratory flow, midexpiratory phase (FEF 25 -75% ), three spirometric measurements (PneumoCheck Spirometer, No. 61000; Welch Allyn, Skaneateles Falls, New York, USA) were taken in each patient before the patient was assigned to a treatment group. Only patients with the most consistent values among these three measurement were selected for the study. The patients were evaluated clinically and spirometrically at the end of each 6-month treatment period, using the Silverman-Andersen score and spirometric measurements. In addition, before the beginning of the study and at the end of each month during the treatment period, patients were questioned about their treatment, the number of asthma attacks they had had, the nature of their asthma presentation, and whether hospitalization had been required. The medical personnel who performed the clinical evaluations and the FEV 1 and FEF 25 -75% measurements for each patient were blind to the patient's treatment.
STATISTICAL ANALYSIS
Data are presented either as the mean and standard deviation or as a percentage, as appropriate. To compare mean values for FEV 1 26 This parameter can be used, with other data, to indicate whether the benefit offered by a new therapy is greater than the effort and cost involved in its acquisition or implementation. For all statistical tests, we used the 95% confidence interval and considered a result significant when P < 0.05.
Results
Forty patients were included in the study, 20 in the group treated with forskolin and 20 in the group treated with sodium cromoglycate. The age range was 12 -45 years and the mean age was 28.9 years. Table 1 shows the general characteristics of the treatment groups at the beginning of the study. There were no significant differences in the clinical or spirometric variables. A paired comparison of FEV 1 and FEF 25 -75% values for the two treatment groups showed no significant differences during the 6 months of treatment ( Table 2) . Although ANOVA for repeated measurements did not show a significant difference over time within either group, a paired Student's t-test comparison between the initial (baseline) and final (6 months) measurements of FEV 1 and FEF 25 -75% provided the following values: forskolin group, FEV 1 , P = 0.004; FEF 25 -75% , not significant; sodium cromoglycate group, FEV 1 , not significant, FEF 25 -75% , P = 0.02. On the other hand, an unpaired comparison between the two groups for FEV 1 and FEF 25 -75% values at the beginning of the treatments did not show a significant difference. These results indicate that the two groups were homogeneous at the start of the study. The percentage of patients who experienced asthma attacks during the 6 months of treatment was significantly lower for the forskolin-treated group (40%; eight patients) than for the group given sodium cromoglycate (85%; 17 patients) (P = 0.003). Among the patients who reported asthma attacks (n = 25), no patient from the forskolin group required hospitalization, whereas three patients (15%) from the group treated with sodium cromoglycate did so. In total, the patients treated with forskolin experienced 16 asthma attacks during the 6 months of treatment, whereas patients in the sodium cromoglycate group experienced 33 attacks. As mentioned above, in the 6 months of treatment, 85% (n = 17) of patients in the sodium cromoglycate group experienced asthma attacks, whereas 40% of patients in the group treated with forskolin experienced asthma attacks (n = 8). The ARR was 45%, whereas the RR (risk of experiencing asthmatic attacks during the 6 months of treatment) for the group treated with forskolin compared with the group treated with sodium cromoglycate was 47%. The RRR for forskolin treatment (reduction in the risk of experiencing asthmatic attacks during the 6 months of treatment, compared with sodium cromoglycate treatment) was 52.9%. The number needed to treat was 2.2 patients. Patient treatment with sodium cromoglycate was monitored by checking the number of inhalations delivered by each container (each container provides 112 inhalations of sodium cromoglycate) and reviewing the duration of use of each 
Discussion
Forskolin possesses anti-inflammatory and antioxidant actions, which have been used in the treatment of the tachyphylaxis observed with salbutamol. 7,8,13 -22 It is known that forskolin activates adenyl cyclase, increasing the level of intracellular cAMP in all eukaryotic cells. 10, 11 One possible mechanism to explain the forskolin-mediated increase in FEV 1 and lessening of asthmatic attacks could be through bronchial muscle relaxation via the activation of membrane maxi-K channels resulting from a forskolininduced increase in cAMP levels and cAMP-dependent phosphorylation. 27 Some allergic processes, such as asthma and eczema, are characterized by a relative diminution in the cAMP levels in cells in the intestine and bronchial muscles. On this basis, we suggest that forskolin might be useful as an anti-spasmodic drug at the level of the intestine or bronchi and consequently for long-term use in the treatment of asthma. To our knowledge, forskolin has not been recommended as a preventive drug in the treatment of asthma or as a long-term drug in the treatment of asthmatic attacks in humans and only a few publications refer to its empirical use, with apparently favourable results. 4 We therefore designed the present study, following clinical trials criteria, to explore whether scientific support could be obtained for the use of forskolin against asthma. A primary requirement for a drug under consideration as a prophylactic treatment for asthma is that its use should reduce the number of asthma attacks or the severity of asthma.
An accepted way to evaluate pulmonary function in a patient with obstructive bronchial pathology, as in asthma, is to make FEV 1 measurements. 28 A major obstruction in air flow correlates well with a reduction in FEV 1 , and an increase in this parameter correlates well with clinical improvement. 28 In our study, a paired comparison of FEV 1 and FEF 25 -75% values did not show a significant difference between the two treatments, and the FEV 1 and FEF 25 -75% values were well maintained in each group. However, in the forskolin-treated group FEV 1 increased significantly when a paired Student's t-test comparison was made between the values obtained at the beginning and end of the 6-month treatment period but this was not the case for FEF 25 -75% . In the sodium cromoglycate group, a paired comparison between the initial and final FEF 25 -75% values also revealed a significant difference, but this was not the case for FEV 1 . We can infer that both treatments are effective in improving pulmonary function in patients with mild persistent or moderate persistent asthma.
As the primary aim of this clinical trial was to evaluate the effectiveness of forskolin extract capsules as a long-term treatment, the most important variable was the number of asthma attacks experienced during the 6 months of treatment. We found that the use of forskolin allowed 60% (n = 12) of treated patients to remain free of asthma attacks during the 6 months of treatment, whereas only 15% of the patients treated with sodium cromoglycate stayed free of asthmatic attacks during the same period of treatment, giving a relative risk reduction (RRR) of 52.9%.
The use of information on risks and the number needed to treat helps in the understanding of the clinical potential of a given treatment. For example, our data indicate that forskolin reduced the risk of asthmatic attacks in 52.9% of the patients; this indicates that, in a series of forskolin-treated patients, an equivalent of 2.2 treated patients would be sufficient to avoid an asthmatic crisis. It seems that forskolin will be more effective than sodium cromoglycate. Additional advantages of forskolin over sodium cromoglycate are the comfort factor (only one dose per day is necessary) and its lower cost (US$14 for 2 months of treatment compared with approximately US$26 for a sodium cromoglycate flask sufficient for only 18 days of treatment). The low cost of forskolin capsules should make this treatment readily available to most of the population. We felt that it was important to have a reliable evaluation of the effectiveness of forskolinhence our use of a single-blinded clinical trial -and to use the methodology of evidence-based medicine to determine the internal and external validity of this study. Until now, forskolin has been used only empirically to treat various diseases and pathologies, but a number of studies have demonstrated its efficacy in the experimental sphere. 7,8,13 -22 It seems probable that forskolin, by virtue of its action on cAMP levels and its antiinflammatory and antioxidant effects, could be used to treat several other diseases. Indeed, a recent study has shown that forskolin can be used to regulate the insulin gene. 29 Finally, it is important to emphasize that, although there is an arguable role for sodium cromoglycate as a prophylactic treatment for asthma in children, 30 we included both children and adults in the present study. However, it will be important to perform more studies to establish the real value of forskolin in several diseases, and more studies will be needed in patients with asthma to confirm our results.
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